IP Library Granted Patent US 9,617,250
Granted Patent B2
US 9,617,250 · App. 14/777,444 · Granted Apr 11, 2017

Pyridin-4-yl derivatives

Inventors: Martin Bolli (Allschwil, CH); Cyrille Lescop (Allschwil, CH); Oliver Nayler (Allschwil, CH); Beat Steiner (Allschwil, CH)
Assignee: ACTELION PHARMACEUTICALS LTD.
C07D413/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,617,250
App. No.
14/777,444
Granted
Apr 11, 2017
Kind
B2
Abstract

The invention relates to compounds of the Formula (I), Formula (I) wherein R 1 and R 2 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Claims (31)

1. A compound of Formula (I),

wherein

R 1 represents C 2-5 -alkyl or cyclopentyl; and

R 2 represents —OCH 2 —CH(OH)—CH 2 —NHCO—CH 2 OH;

or a salt thereof.

2. A compound according to claim 1 , wherein R 1 represents ethyl, n-propyl, isopropyl, n-butyl, isobutyl, isopentyl, pent-3-yl, or cyclopentyl, or a salt thereof.

3. A compound according to claim 1 , wherein R 1 represents n-propyl, isopropyl, isobutyl, or cyclopentyl, or a salt thereof.

4. A compound according to claim 1 , wherein R 1 represents cyclopentyl, or a salt thereof.

5. A compound according to claim 1 , wherein the stereocenter of the

R 2 group —OCH 2 —CH(OH)—CH 2 —NHCO—CH 2 OH is in the S-configuration, or a salt thereof.

6. A compound according to claim 1 selected from the group consisting of:

(S)—N-(3-(2-ethyl-4-(5-(2-ethylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)—N-(3-(2-ethyl-4-(5-(2-propylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)—N-(3-(2-ethyl-4-(5-(2-isopropylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)—N-(3-(2-ethyl-4-(5-(2-butylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)—N-(3-(2-ethyl-4-(5-(2-isobutylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)—N-(3-(2-ethyl-4-(5-(2-isopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)—N-(3-(2-ethyl-4-(5-(2-(pentan-3-yl)-pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide; and

(S)—N-(3-(2-ethyl-4-(5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

or a salt of any such compound.

7. A compound according to claim 1 which is (S)—N-(3-(2-ethyl-4-(5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxyproplyl)-2-hydroxyacetamide or a salt thereof.

8. A pharmaceutical composition comprising

a compound according to claim 1 , in free or pharmaceutically acceptable salt form, and

a pharmaceutically acceptable carrier.

9. A compound according to claim 1 which is (S)—N-(3-(2-ethyl-4-(5-(2-ethylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide or a salt thereof.

10. A pharmaceutical composition comprising

a compound according to claim 7 , in free or pharmaceutically acceptable salt form, and

a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising

a compound according to claim 9 , in free or pharmaceutically acceptable salt form, and

a pharmaceutically acceptable carrier.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: IDORSIA PHARMACEUTICALS LTD.
To: VIATRIS ASIA PACIFIC PTE. LTD.
Reel/Frame 067647/0303 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2015
From: BOLLI, MARTIN; LESCOP, CYRILLE; NAYLER, OLIVER; STEINER, BEAT
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 036672/0304 →
Priority Claims (1)
EP 13159482 · Mar 15, 2013 · regional
Continuity (1)
Related Publication 20160031866A1 · Feb 4, 2016